RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe
Varas-Lorenzo, C., Garcia-Rodriguez, LA., Cattaruzzi, C., Troncon, MG., Agostinis, L., & Perez-Gutthann, S. (1998). Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe. American Journal of Epidemiology, 147(4), 387-390.
The authors evaluated the risk of venous thromboembolism associated with hormone replacement therapy in a cohort of 265,431 women aged 45-79 years who did not have major risk factors for venous thromboembolism. Through review of hospital charts, 171 cases were confirmed (pulmonary embolism = 77; deep venous thrombosis = 94). Ten thousand controls were randomly sampled. The risk of venous thromboembolism among nonusers of hormone replacement therapy was 1.3 per 10,000 women per year. Current users of hormone replacement therapy had 2.3 times higher risk of venous thromboembolism (95 percent confidence interval 1.0-5.3) compared with nonusers. The increased risk was restricted to the first year of treatment
